Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC
Key facts
- Who runs it
- MedImmune LLC
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Oct 2020
- Ended
- 19 Mar 2024
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard of Care - mFOLFOX6
- E1 - mFOLFOX and durvalumab
- E2 - mFOLFOX6, durvalumab and oleclumab
- E3 - mFOLFOX6, durvalumab and monalizumab
- Record updated
- 21 September 2020
- Why it stopped
- Study withdrawn prior to enrollment due to changing standard of care landscape.
Who can take part
- Age
- 18 years to 101 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Written informed consent and any locally required authorization obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
- Age ≥ 18 years at the time of screening
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically proven Stage II or Stage III CRC; Subjects must also meet the following criteria:; Eligible for 6 months of mFOLFOX6 adjuvant chemotherapy within 8 weeks after surgery; Must NOT have received prior systemic chemotherapy, immunotherapy, or radiotherapy for treatment of CRC; Must NOT have defective DNA mismatch repair (MSI) as documented by testing
- Margin-negative (R0; defined as >1 mm clearance) surgical resection
- Postoperative ctDNA-positive status defined by the presence of ctDNA derived from plasma; determined using a validated assay per protocol
- Subjects must have adequate organ function
- Body weight > 35 kg
- Adequate method of contraception per protocol
Who cannot take part
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
- Active or prior documented autoimmune disorders within the past 5 years as noted in the protocol
- History of another primary malignancy except for: (a) Malignancy treated with curative intent and with no known active disease ≥ 5 years prior to the scheduled first dose of study treatment and of low potential risk for recurrence
- Known allergy or hypersensitivity to any of the investigational product or noninvestigational product formulations
- Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the scheduled first dose of study treatment, or anticipation of the need for major surgical procedure during the course of the study
- Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment
- Evidence of metastatic disease (including presence of tumor cells in ascites or peritoneal carcinomatosis resected "en bloc")
- History of allogeneic organ transplantation
- Uncontrolled intercurrent illness, see the protocol for details
- History of active primary immunodeficiency
- Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
- Any condition that, in the opinion of the investigator, would prevent the initiation of 6 months adjuvant therapy within 8 weeks of surgery
- Cardiac and vascular criteria:; History of venous thrombosis within the past 3 months prior to the scheduled first dose of study treatment; Presence of acute coronary syndrome including myocardial infarction or unstable angina pectoris, other arterial thrombotic event including cerebrovascular accident or transient ischemic attack or stroke within the past 6 months prior to the scheduled first dose of study treatment; New York Heart Association (NYHA) Class II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or uncontrolled hypertension; History of hypertensive crisis/hypertensive encephalopathy within the past 6 months prior to the scheduled first dose of study treatment; Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms
About the trial
What the trial wants to find out
Columbia 2 is a Phase 2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX) alone and in combination with novel oncology therapies in adjuvant high-risk microsatellite-stable colorectal cancer
The 4 groups in the trial
- Control Arm (mFOLFOX6)Existing treatment, for comparison
Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
Treatment: Standard of Care - mFOLFOX6, E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6, durvalumab and oleclumab, and E3 - mFOLFOX6, durvalumab and monalizumab
- DurvalumabTreatment being tested
Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)
Treatment: E1 - mFOLFOX and durvalumab, E2 - mFOLFOX6, durvalumab and oleclumab, and E3 - mFOLFOX6, durvalumab and monalizumab
- OleclumabTreatment being tested
Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)
Treatment: E2 - mFOLFOX6, durvalumab and oleclumab
- MonalizumabTreatment being tested
Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)
Treatment: E3 - mFOLFOX6, durvalumab and monalizumab
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Open-label, Randomized, Multicenter, Platform Study of Novel Oncology Therapies in Combination With Adjuvant Chemotherapy in High-risk, Microsatellite-stable Colorectal Cancer (COLUMBIA-2)
- Record updated
- 21 September 2020